Published in J Biomed Biotechnol on December 28, 2010
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability. Br J Cancer (2014) 0.79
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS One (2012) 0.79
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 16.57
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
The CBP co-activator is a histone acetyltransferase. Nature (1997) 10.91
Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev (1999) 7.42
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 6.15
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
CREB-binding protein and p300 in transcriptional regulation. J Biol Chem (2001) 4.67
The endocrinology and developmental biology of the prostate. Endocr Rev (1987) 3.58
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci U S A (1996) 3.43
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer (2009) 3.33
p300/CBP and cancer. Oncogene (2004) 3.13
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem (2004) 3.13
Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem (1991) 2.79
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci U S A (1996) 2.41
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60. J Biol Chem (1997) 2.12
The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem (1998) 2.08
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A (2003) 1.99
Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem (2002) 1.95
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem (1997) 1.92
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem (2002) 1.90
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol (2004) 1.86
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res (1996) 1.78
Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res (2007) 1.75
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Histone acetyl transferases as emerging drug targets. Drug Discov Today (2009) 1.64
A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis. Nucl Recept Signal (2008) 1.62
Structural basis for the nuclear import of the human androgen receptor. J Cell Sci (2008) 1.53
Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci U S A (1998) 1.51
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res (2007) 1.35
Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol (2004) 1.34
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J (2005) 1.27
Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer (2010) 1.26
Androgen receptor corepressors: an overview. Prostate (2005) 1.25
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 1.24
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer (2006) 1.16
The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem (2004) 1.14
Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors (2009) 1.13
Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem (2001) 1.07
The role of androgen receptor mutations in prostate cancer progression. Curr Genomics (2009) 1.07
DNA recognition by nuclear receptors. Essays Biochem (2004) 1.04
The functional significance of nuclear receptor acetylation. Steroids (2007) 1.04
Nuclear receptor modifications and endocrine cell proliferation. J Steroid Biochem Mol Biol (2003) 0.99
A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell Mol Life Sci (2010) 0.93
Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat (2009) 0.90
Posttranscription regulation of prostate cancer growth. Cancer J (2008) 0.88
HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene (2009) 0.87
The hinge region of the androgen receptor plays a role in proteasome-mediated transcriptional activation. Ann N Y Acad Sci (2004) 0.86
Androgen and estrogen receptors: potential of crystallography in the fight against cancer. Int J Biochem Cell Biol (2007) 0.84
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet (2012) 1.19
Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene (2004) 1.16
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res (2010) 0.96
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer (2009) 0.95
Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control. J Biol Chem (2002) 0.92
Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol (2010) 0.89
Visualising androgen receptor activity in male and female mice. PLoS One (2013) 0.89
Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors. J Biol Chem (2011) 0.88
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Mol Cell Endocrinol (2013) 0.86
Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol Endocrinol (2012) 0.85
Proteomic analysis of proteins regulated by TRPS1 transcription factor in DU145 prostate cancer cells. Biochim Biophys Acta (2007) 0.83
Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Expert Rev Mol Diagn (2013) 0.81
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Clin Cancer Res (2004) 0.81
Circulating nucleic acids as biomarkers of prostate cancer. Biomark Med (2013) 0.76
Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget (2014) 0.76
Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer. Cell Signal (2010) 0.75